PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Dalbergin (DGN) and isoliquiritigenin (ISG) from heartwood demonstrated antidiabetic potential in-vitro and in-vivo, with ISG showing 99.05% inhibition of alpha amylase activity [PMID:38740667]
Hydro-ethanolic bark extract (DLBE) was evaluated for anti-obesity activity in high fat diet induced obese rats [PMID:33134011]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 41168759 (2025) — Predicting habitat suitability of Dalbergia latifolia Roxb. (Indian rosewood) using MaxEnt: implications for conservation and sustainable forest management. · BMC ecology and evolution
- 2.PMID: 30989982 (2019) — [Study on neoflavonoids from heartwood of Dalbergia latifolia]. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
- 3.PMID: 23965430 (2013) — Earthworm-derived pore-forming toxin lysenin and screening of its inhibitors. · Toxins
- 4.PMID: 4261471 (1972) — An unusual case of rosewood dermatitis of the genus Dalbergia (East Indian rosewood). · British journal of industrial medicine
- 5.PMID: 8896971 (1996)